Evidence map›Paper›PMID 39829533›Full record

ArticleACS omega2025

Discovery of 2-Pyrazolines That Inhibit the Phosphorylation of STAT3 as Nanomolar Cytotoxic Agents.

Tejaswini P Siddappa, Akshay Ravish, Zhang Xi, Arunkumar Mohan, Swamy S Girimanchanaika, Niranjan Pattehali Krishnamurthy, Shreeja Basappa, Santosh L Gaonkar, Peter E Lobie, Vijay Pandey and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. STAT3 signaling inhibitors for cancer treatment.Trends in pharmacological sciences · 2026
    Review
  2. Imidazo[1,2‑ACS omega · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Tejaswini P SiddappaLaboratory of Chemical Biology, Department of Studies in Organic Chemistry, University of Mysore, Mysore, Karnataka 570006, India.ORCID https://orcid.org/0009-0006-8763-7689
Akshay RavishLaboratory of Chemical Biology, Department of Studies in Organic Chemistry, University of Mysore, Mysore, Karnataka 570006, India.
Zhang XiShenzhen Bay Laboratory, Shenzhen 518055, China.ORCID https://orcid.org/0000-0003-4093-0897
Arunkumar MohanLaboratory of Chemical Biology, Department of Studies in Organic Chemistry, University of Mysore, Mysore, Karnataka 570006, India.ORCID https://orcid.org/0009-0009-2058-8386
Swamy S GirimanchanaikaLaboratory of Chemical Biology, Department of Studies in Organic Chemistry, University of Mysore, Mysore, Karnataka 570006, India.
Niranjan Pattehali KrishnamurthyNMR Research Centre, Indian Institute of Science, Bangalore, Karnataka 560012, India.
Shreeja BasappaDepartment of Chemistry, BITS-Pilani Hyderabad Campus, Jawahar Nagar, Medchal 500078, India.
Santosh L GaonkarDepartment of Chemistry, Manipal Institute of Technology, Manipal Academy of Higher Education, Manipal, Karnataka 576104, India.
Peter E LobieShenzhen Bay Laboratory, Shenzhen 518055, China.
Vijay PandeyInstitute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, China.
Basappa BasappaLaboratory of Chemical Biology, Department of Studies in Organic Chemistry, University of Mysore, Mysore, Karnataka 570006, India.ORCID https://orcid.org/0000-0002-8844-468X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

STAT3 has emerged as a validated target in cancer, being functionally associated with breast cancer (BC) development, growth, resistance to chemotherapy, metastasis, and evasion of immune surveillance. Previously, a series of compounds consisting of imidazo[1,2-

Identifiers

PMID39829533
PMCPMC11740381

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.